Organisation paid for research Program year 2025 Source: CMS Open Payments

Pharmaseek Financial Services LLC

Neither a doctor nor a teaching hospital

Research payments

$6,182,898

1,081 payments

Through program year 2025, Pharmaseek Financial Services LLC is reported as receiving $6,182,898 in research payments, across 1,081 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$6,500	1
2024	Research	$25,000	3
2023	Research	$56,335	10
2022	Research	$234,498	213
2021	Research	$262,072	177
2020	Research	$1,873,668	294
2019	Research	$3,724,824	383

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $1,377,214 19 payments
Janssen Research & Development, LLC $965,563 57 payments
AbbVie, Inc. $857,417 141 payments
Allergan Inc. $763,468 177 payments
Novo Nordisk AS $584,956 151 payments
Kowa Research Institute, Inc. $419,269 36 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $184,693 12 payments
Esperion Therapeutics, Inc. $182,324 296 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $128,955 4 payments
E.R. Squibb & Sons, L.L.C. $122,057 6 payments

Studies the money was for Research payments · program years 2019–2025

An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression $848,743 51 payments
M16-100 $663,804 105 payments
A Study of Tirzepatide (Ly3298176) Once A Week Versus Insulin Glargine Once A Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk $406,344 5 payments
A Randomized, Phase 3, Open-Label Trial Comparing the Effect of Ly3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes $401,690 3 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. $395,355 61 payments
K-877-302 $237,764 21 payments
A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly As Add-On Therapy to Metformin in Patients With Type 2 Diabetes $236,170 2 payments
Nn1250-4419 $193,422 13 payments
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $182,324 296 payments
K-877-302 $181,505 15 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.